Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
P/B ratio for Enanta Pharmaceuticals, Inc. (ENTA)
P/B ratio as of 2024: 1.70
According to Enanta Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.70. At the end of 2023 the company had a P/B ratio of 1.08.
P/B ratio history for Enanta Pharmaceuticals, Inc. from 2010 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 1.70 |
| 2023 | 1.08 |
| 2022 | 3.33 |
| 2021 | 2.87 |
| 2020 | 2.00 |
| 2019 | 2.54 |
| 2018 | 4.41 |
| 2017 | 2.96 |
| 2016 | 1.87 |
| 2015 | 2.86 |
| 2014 | 4.89 |
| 2013 | 2.03 |
| 2012 | 0.45 |
| 2011 | -0.15 |
| 2010 | 0.00 |